Several trials and reviews provide evidence for the efficacy of phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction (ED). However, little is known about the impact of treatment effect modifiers other than concomitant diseases. Our objective was to identify patient and trial characteristics as well as methodological and publication-related issues that are associated with the treatment effect measured in flexible-dose randomized controlled trials of oral sildenafil for ED. The MEDLINE and the Cochrane Central databases were searched for efficacy trials of sildenafil. Thirteen trials fulfilled all inclusion criteria. A series of meta-regression and graphical analyses were performed to test the impact of possible effect modifiers. Treatment effect was influenced by mean baseline disease severity and mean duration of the disease. These associations were at least partly mediated by placebo response. Trial duration, age of patients and etiology of ED in patients did not have any significant influence on the treatment effect. The year of publication of primary trials was also related to trial findings. Our analysis adds important data to enable the control of confounding variables in future trials and meta-analyses. It might also help the individual to assess the unbiased efficacy and true innovative potential of available and forthcoming pharmacological agents.
Introduction
Erectile dysfunction (ED), the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual activity, affects around 15-25% of the world's male population. [1] [2] [3] Among a wide variety of available treatments for ED, the oral administration of phosphodiesterase-5 (PDE-5) inhibitors represents an attractive and widely used therapeutic option.
Numerous trials, overviews and systematic reviews provide evidence of the efficacy and safety of the three approved agents: sildenafil, tadalafil and vardenafil. [4] [5] [6] [7] [8] [9] Phosphodiesterase-5 inhibitors were and are being tested in several patient populations with various concomitant diseases and therapies, for example type II diabetes mellitus, coronary artery disease, congestive heart failure, multiple sclerosis, spinal bifida, spinal cord injury, depression, history of radical prostatectomy, in patients with concomitant use of serotonin reuptake inhibitors or antihypertensive drugs. However, this strong 'comorbidity-driven' interest led to a situation in which determinants of treatment effect other than concomitant disease have so far been neglected. Although some of the primary studies analyze efficacy in patient subgroups, the study reports go rarely beyond simple description, and statistical testing of confounding effects is not even performed in meta-analyses. [10] [11] [12] The objective of the present meta-analytic regression analysis was to investigate various possible treatment effect modifiers in trials with oral sildenafil for ED. We considered (1) core parameters that can function as mediators or moderators of the treatment effect (such as trial and patient characteristics) and (2) distorting issues that can bias study findings and their dissemination (such as bias relating to methodological quality and publication).
Materials and methods

Identification of trials
The by far largest study database on a PDE-5 inhibitor is provided by sildenafil (manufactured by Pfizer Inc., New York, NY, USA). We, therefore, restricted our search to trials of this agent. Owing to possible efficacy differences between agents, inclusion of all three approved PDE-5 inhibitors at this point would have led to an unnecessary increase in heterogeneity between primary study results. 9, 13 In October 2005, the MEDLINE and the Cochrane Central Register of Controlled Trials (CCTR) databases, were searched for randomized placebo-controlled efficacy trials of sildenafil. In the electronic search, the substance and trade names were combined with the truncated terms 'effic*' and 'effec*'. The national branch of the drug manufacturer was asked to provide further information. References of the identified articles and reviews on sildenafil were searched for other relevant publications.
Inclusion of trials
All identified publications were screened independently by two reviewers (L Kriston and A Harms). Trials were included, if they fulfilled all of the following criteria: (1) randomized and controlled by placebo (RCT); (2) parallel-group or crossover design; (3) double-blinding; (4) administering flexible-dose drug regimen; (5) conduction in broad-spectrum sample with ED; (6) administering the International Index of Erectile Functioning (IIEF) 14, 15 and (7) reporting relevant outcome, at least mean and sample size. Any disagreement between reviewers was resolved by involving a third reviewer (MM Berner) to decide.
Data extraction
Basic data were extracted by L Kriston using a structured form that included the following information: authors; year and language of publication; sample size; duration of treatment; age and ethnicity of patients; baseline severity, etiology and duration of ED in patient population.
Methodological quality was assessed by L Kriston by means of the Jadad Score. 16 Owing to the inclusion criteria (randomization and double-blinding), all studies scored at least two points on Jadad's scale. Further three points could be obtained by describing the (appropriate) randomization, (appropriate) double-blinding method and the study dropouts.
The primary outcome was the efficacy measured by means of the erectile function (EF) domain score of the IIEF for both placebo and sildenafil groups (mean difference after treatment). In case of insufficiently reported data, standard deviations were extracted from figures or imputed according to the recommendations of the Cochrane Collaboration. 17 The extraction was based either on figures presenting confidence intervals, standard errors or standard deviations. Data imputation was performed on the basis of exactly reported P-values, or on other comparable trials that reported standard deviations for treatment and placebo group. Means and sample sizes were not estimated; their insufficient reporting led to study exclusion. From crossover trials, only the first-phase data before switching were extracted. Outcome reports were extracted independently by two reviewers (L Kriston and A Harms). Any disagreement was resolved by discussion.
Statistical analysis
Inverse variance-weighted meta-regression models were used to test the impact of core effect modifiers (1) mean trial duration, (2) mean age, (3) mean baseline EF score, (4) proportion of men with psychogenic etiology and (5) mean ED duration of patients on the mean post-treatment EF domain score of the placebo group and of the sildenafil group, as well as on the mean treatment effect (difference in mean post-treatment EF scores between sildenafil and placebo groups). Finally, the impact of the post-treatment EF domain score of the placebo and the sildenafil groups on the treatment effect was investigated. For graphical demonstration, the L'Abbé plot of post-treatment EF domain score of the sildenafil group against the posttreatment EF domain score in the placebo group was prepared. 18 To examine possible sources of bias, a second group of regression analyses were planned to investigate the effect of the following distorting factors on the treatment effect: (1) sample size; (2) methodological quality; (3) year of publication and (4) impact factor of publishing journal in year of publication. To detect possible publication bias, visual examination of funnel plot (scatter plot of treatment effect against sample size) and Egger's test (regression of treatment effect on its standard error) were performed. 19 All meta-regression analyses were performed using the restricted maximum likelihood estimate method, a recommended random effect approach that accounts for residual between-trial heterogeneity. 20, 21 Owing to power considerations, we could not use multiple meta-regression, but fitted univariate models instead. To test possible associations between effect modifiers, intercorrelations (Pearson's r) were calculated.
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Results
Included trials
Fifty-six RCTs that investigated efficacy of oral sildenafil for ED were identified. Of them, a total of 13 trials fulfilled all inclusion criteria and were included in the meta-regression analysis. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Characteristics of the included trials are presented in Table 1 .
Core effect modifiers
In regression analyses, baseline EF domain score of patients was strongly associated with the posttreatment EF domain score in the placebo group (see Table 2 ). Patients with higher baseline EFdomain score (i.e. with an ED of minor severity) showed larger placebo response (b ¼ 0.884, Po0.001). No confounder was significantly associated with the post-treatment EF domain score in the sildenafil group. Treatment effect was significantly associated with baseline EF domain score (trials in less severe patients showing decreased effect, b ¼ À0.770, Po0.001) and ED duration in patients (with trials of patients with a longer ED history showing larger effect, b ¼ 0.668, P ¼ 0.002). In further analyses, treatment effect was strongly associated with the post-treatment EF domain score of the placebo group (b ¼ À0.835, Po0.001), but not with the post-treatment EF domain score of the sildenafil group (see Table 2 ).
The L'Abbé plot showed high stability of posttreatment EF domain score in the sildenafil group at large variation of the post-treatment EF domain scores in the placebo group (b ¼ 0.388, P ¼ 0.159) (Figure 1 ).
Correlation analysis of core factors showed low non-significant interrelations.
Distorting effect modifiers
Of the factors related to methodological quality and publication process, the impact of methodological quality (by Jadad's scale) could not be investigated owing to extremely low variation in the independent variable (11 of 13 studies scored three points). Of the other factors, only year of publication was associated with treatment effect, with early trials showing larger effects (b ¼ À0.626, P ¼ 0.006; see Table 2 ).
The correlation analysis of the distorting confounders showed none to weak inter-relation of variables, with the exception of the moderately strong negative-association between year of publication and the impact factor of the publishing journal in the same year (r ¼ À0.610, P ¼ 0.027).
The visual examination of the funnel plot (see Figure 2 ) and Egger's test did not reveal any evidence for publication bias (b ¼ 0.269, P ¼ 0.858).
Discussion
In the present study, we identified some factors that could explain heterogeneity between primary findings on the efficacy of flexible-dose oral sildenafil for ED.
Our findings are based on a methodology that has several limitations. First, meta-regression analyses can lead to false-positive results, indicating associa- A meta-regression analysis of treatment effect modifiers L Kriston et al tions that are caused rather by chance than by true association. 36 We, therefore, tried to avoid incorrect conclusions by using a method that allows for an additive component of residual heterogeneity. 21 Second, inferences drawn from a meta-regression analysis on aggregate data may differentiate from inferences drawn from a meta-regression analysis on individual data (e.g. 'ecological bias'). 37, 38 Third, the fitting of univariate models does not allow for the simultaneous control of the other effect modifiers. However, given the limited number of available trials, the application of multivariate meta-analyses would have probably led to more spurious findings. 36 To ease interpretation, we analyzed the correlation matrix of the possible effect modifiers. Fourth, for funnel plot, we used the more traditional method of sample size as a measure of precision, A meta-regression analysis of treatment effect modifiers L Kriston et al rather than the recommended standard error of treatment effect. 39 We made this decision, because standard deviations, which are components of the standard error, had to be substituted in some cases. To ensure correct conclusions, additionally Egger's test was performed. Fifth, we had to restrict our analyses to a limited number of possible effect modifiers with high plausibility. Some other core factors (e.g. preferred dose) and distorting aspects (e.g. role of funding source) might also affect trial results. Sixth, it cannot be excluded that efficacy measures other than the EF domain score of the IIEF (e.g. number of responders) may be more robust against the impact of the examined effect modifiers, or may be affected by other ones. Nevertheless, this measure in general opinion represents a valid estimate of treatment efficacy. 14, 15 Considering core aspects, the baseline functioning (EF domain score before treatment) proved to be the strongest modifier of treatment effect. This finding is also reported by several open-label studies. [40] [41] [42] [43] It could also be demonstrated that the variance in treatment effect is mainly determined by the variance in the placebo response and not by that in the sildenafil group. Combining these findings, one can argue that the variance in treatment effect is mostly owing to the variance in baseline functioning, mediated by the placebo response.
Another fairly independent predictor of treatment effect is the duration of ED in patients. It is negatively associated with response in the placebo group (longer disease is likely to lead to lower response) and positively in the sildenafil group (longer disease is likely to lead to higher response). These two effects, although separately not significant, explain together a meaningful part of heterogeneity in treatment effect between primary study results. Previous studies did not find an association between ED duration and treatment effect. 40, 44 However, they examined only groups receiving sildenafil regardless of placebo response.
Trial duration, age of patients and etiology of ED in patients did not have any significant influence on the treatment effect. Also in previous studies, age did not prove to be significantly associated with response to sildenafil, when other factors were controlled. 40, 42, 44 The clinical experience that older patients show, worse response to sildenafil than younger ones, is possibly put down to the association of age with baseline severity and concomitant diseases. Findings on etiology as an effect modifier are inconsistent, with the majority of trials showing an effect. [40] [41] [42] 44 A trial indicating no effect of etiology was reported by Shabsigh. 45 However, impact of etiology is mostly due to low response rates of patients with serious concomitant diseases (e.g. following radical prostatectomy). The fact that such patients are excluded from the analyzed 'broad-spectrum' trials might be responsible for finding no effect.
Of the methodological factors that can possibly bias trial results, there was no correlation found between size and finding of the trials. The year of publication was negatively associated with treatment efficacy estimates, with earlier published trials reporting larger effects. This is concordant with the empirical evidence for the so-called time lag bias, the finding that trials with (more) positive results are faster published than negative ones. 46, 47 The moderately strong negative-association between publication year and the impact factor of the publishing journal in the same year suggests that more desirable results are probably published, not only earlier but also in journals with higher impact factors than trials showing smaller effects. Nevertheless, the latter statement is not confirmed by a direct inter-relation of impact factor and treatment effect.
We found no evidence of other aspects of publication bias. Both the funnel plot and Egger's test suggested that most relevant trials were published.
In our study, we tried to contribute to the understanding of treatment effect in trials with flexibledose oral sildenafil for ED in broad-spectrum populations. We conclude that patient characteristics (mainly baseline severity and duration of disease) can seriously affect findings of efficacy trials, although the agent sildenafil itself has a reliable effect, almost fully irrespective of them. Variation in trial findings is mostly caused by varying responses to placebos. It is a fact that clinicians, investigators, clinical guideline developers, policy makers and economic evaluators must be aware of when performing a study, interpreting trial results or applying them to their patient population.
The presented methods can be used in further analyses of primary studies with other approved PDE-5 inhibitors (tadalafil, vardenafil) as well. As a possible effect modifier, the often-discussed impact of sildenafil experience on trial results could also be investigated. Our results provide solid bases for adjustment factors in future comparative trials and meta-analyses, which might, therefore, enable the individual to gain a view on the true innovative potential of new medications in the present and future.
